Neuvivo Appoints Mark Henderson, PhD, to Lead Manufacturing for ALS Treatment

Thursday, 22 August 2024, 06:09

Neuvivo, a leader in ALS treatment development, has appointed Mark Henderson, PhD, as Vice President of Manufacturing. This strategic move aims to fortify Neuvivo's technical operations for their investigational therapies targeting Amyotrophic Lateral Sclerosis. Henderson's expertise will likely enhance their innovative efforts in neurodegenerative disease treatment.
LivaRava_Technology_Default_1.png
Neuvivo Appoints Mark Henderson, PhD, to Lead Manufacturing for ALS Treatment

Neuvivo Strengthens Technical Operations

Neuvivo, a biopharmaceutical company focused on groundbreaking therapies for Amyotrophic Lateral Sclerosis (ALS), announced the significant appointment of Mark Henderson, PhD, as Vice President of Manufacturing. This role is pivotal in enhancing technical operations and ensuring the success of their investigational ALS treatment.

Impact of the Appointment

  • Dr. Henderson brings a wealth of experience in manufacturing and operations.
  • His role will accelerate the development and production processes for Neuvivo’s therapies.
  • The strategic appointment signals Neuvivo's commitment to advancing treatments for neurodegenerative diseases.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most reliable and up-to-date tech news. Stay informed and elevate your tech expertise effortlessly.

Subscribe